Bioventix (BVXP)

 

BVXP Share PerformanceMore

52 week high1,600.0 17/10/16
52 week low899.5 25/07/16
52 week change -12.0 (-0.98%)
4 week volume145,994 13/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Bioventix resolutions passed at AGM

Bioventix has confirmed that all resolutions put to shareholders at the annual general meeting yesterday were passed. At 8:5...

Result of AGM

Bioventix plc (?Bioventix? or the ?Company?) Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held earlier today, all resolutions put to shareholders were duly passed. For further information please contact: Bioventix plc Peter Harrison Chief Executive Officer Tel: 01252 728 001 finnCap Ltd Geoff Nash/Simon Hicks Stephen N...

Director/PDMR Shareholding

Bioventix plc (?Bioventix? or the ?Company?) Director/PDMR Shareholding Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 18 November 2016 of the following transactions in its ordinary shares of 5 pence each (?Ordinary Shar...

Notice of AGM

Bioventix plc (?Bioventix? or the ?Company?) Notice of AGM and Posting of Annual Report Bioventix plc (AIM: BVXP) announces that its Annual General Meeting will be held at The Winchester Suite, Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00 p.m. on Wednesday 7 December 2016. Copies of the 2016 Annual Report and the Notice of the Annual General M...

Broker Forecast - finnCap issues a broker note on Bioventix Plc

finnCap today reaffirms its corporate investment rating on Bioventix Plc (LON:BVXP) and raised its price target to 1450p ...

Final Results

Bioventix plc (?Bioventix? or the ?Company?) Preliminary results for the year ended 30 June 2016 Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2016. Highlights: Revenue up 27% to ?5.5 ...

Second Price Monitoring Extn

RNS Number: 1442M BioVentix PLC 10 October 2016 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined percen...

Second Price Monitoring Extn

RNS Number: 1438M BioVentix PLC 10 October 2016 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined percent...

Fundamental DataMore

P/E ratio18.071
EPS69.18
Dividend yield3.4 %

Latest discussion posts More

  • Director Sales

    Not sure I like today's RNS
    7-Dec-2016
    Hardboy
  • Re: Finals

    "but why would anyone sell today" A good question Buy on the rumour and sell on the news. I made a note in late April to buy on the 200x moving average, achieved early ...
    20-Oct-2016
    seadoc
  • Re: Finals

    I know we have had a good rise of late, so profit taking is always likely, but why would anyone sell today>? Might as well hang on for the dividend & special dividend - only ...
    17-Oct-2016
    Hardboy

Users' HoldingsMore

Users who hold Bioventix also hold..
SOMERO ENTER DI38%
LLOYDS GRP.30%
ZYTRONIC26%
GLAXOSMITHKLINE26%
TRAKM8 HLDGS16%

Codes & Symbols

ISINGB00B4QVDF07
SymbolsBVXP, LSE:BVXP, BVXP.L, BVXP:LN, LON:BVXP, XLON:BVXP